Long-acting β-agonist prescribing in people with asthma in primary care

Daniel R. Morales; Catherine Miriam Jackson; Shona Fielding; Bruce Guthrie

doi:10.1136/thoraxjnl-2012-202071

Long-acting β-agonist prescribing in people with asthma in primary care

Daniel R. Morales^*, Catherine Miriam Jackson, Shona Fielding, Bruce Guthrie

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Long-acting beta 2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

Original language	English
Pages (from-to)	192-194
Number of pages	3
Journal	Thorax
Volume	68
Issue number	2
Early online date	1 Sept 2012
DOIs	https://doi.org/10.1136/thoraxjnl-2012-202071
Publication status	Published - Feb 2013

Access to Document

10.1136/thoraxjnl-2012-202071

Cite this

@article{d6dedaae4a3444d79c471fef19db3121,

title = "Long-acting β-agonist prescribing in people with asthma in primary care",

abstract = "Long-acting beta 2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.",

author = "Morales, {Daniel R.} and Jackson, {Catherine Miriam} and Shona Fielding and Bruce Guthrie",

year = "2013",

month = feb,

doi = "10.1136/thoraxjnl-2012-202071",

language = "English",

volume = "68",

pages = "192--194",

journal = "Thorax",

issn = "0040-6376",

publisher = "B M J PUBLISHING GROUP",

number = "2",

}

TY - JOUR

T1 - Long-acting β-agonist prescribing in people with asthma in primary care

AU - Morales, Daniel R.

AU - Jackson, Catherine Miriam

AU - Fielding, Shona

AU - Guthrie, Bruce

PY - 2013/2

Y1 - 2013/2

N2 - Long-acting beta 2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

AB - Long-acting beta 2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

U2 - 10.1136/thoraxjnl-2012-202071

DO - 10.1136/thoraxjnl-2012-202071

M3 - Article

SN - 0040-6376

VL - 68

SP - 192

EP - 194

JO - Thorax

JF - Thorax

IS - 2

ER -

Long-acting β-agonist prescribing in people with asthma in primary care

Abstract

Access to Document

Fingerprint

Cite this